First Ascent Biomedical in the News
First Ascent Biomedical in the News
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in the pediatric cancer population. Survival [...]
Feline injection-site sarcoma (FISS), an aggressive iatrogenic subcutaneous malignancy, is challenging to manage clinically and [...]
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood with an unmet clinical [...]
Diffuse intrinsic pontine glioma (DIPG) is a universally fatal childhood cancer of the brain. Despite [...]
In complex, highly unstable genomes such as in osteosarcoma, targeting aberrant checkpoint processes (metabolic, cell [...]
Rhabdomyosarcoma (RMS) is the most common childhood soft tissue sarcoma. RMS often arise from myogenic [...]
Design of personalized targeted therapies involve modeling of patient sensitivity to various drugs and drug [...]
The prediction of tumor sensitivity to targeted drugs remains a major challenge in the design [...]
Diffuse intrinsic pontine glioma (DIPG) is a fatal childhood cancer. We performed a chemical screen [...]
Diffuse intrinsic pontine gliomas (DIPGs) represent a particularly lethal type of pediatric brain cancer with [...]
A framework for design of personalized cancer therapy requires the ability to predict the sensitivity [...]
Drugs that target specific proteins are a major paradigm in cancer research. In this article, [...]
Alveolar rhabdomyosarcoma (aRMS) is a myogenic childhood sarcoma frequently associated with a translocation-mediated fusion gene, [...]
The success of targeted anti-cancer drugs are frequently hindered by the lack of knowledge of [...]
Drugs targeting specific kinases are becoming common in cancer research and are a basis for [...]
Genetic Regulatory Networks (GRNs) are frequently modeled as Markov Chains providing the transition probabilities of [...]


























